LOEWI GmbH receives seed financing to make personalized health and nutrition available for everyone

June 17, 2020

The Munich-based technology company LOEWI has received new capital from High-Tech Gründerfonds (HTGF) and a German family office in a seed financing round. The scientific spin-off of the Technical University of Munich is one of the technology leaders in the field of personalized nutrition and health and has been mainly active in competitive sports so far. Among LOEWI´s clients are teams and clubs from Tour de France and UEFA Europa League.

The investment is an important step to push the development in the field of personalized nutrition and health and to lead the market out of its niche. The combination of science and technology will continue to be the cornerstone of our business. We are very pleased to welcome HTGF as a well-connected partner who supports our long-term vision.

Adrian Kapsalis, founder and CEO of LOEWI

LOEWI has developed a personalized nutrition solution with a digital health focus. The personalization in nutrition and the potential to leverage user-specific data for novel approaches in nutritional therapy in the future makes the investment in LOEWI particularly exciting.

Dr. Marie Asano, Investment Manager at High-Tech Gründerfonds

LOEWI’s patented concept collects health-relevant data of customers and patients through a blood test and an online anamnesis questionnaire, makes this data available via LOEWI’s Health Profile (Class I medical software) and, with the help of a sophisticated personalization algorithm, creates a personalized nutrient combination that is 100% tailored to the personal needs of each customer and patient.

Every person is unique and has different needs. LOEWI now considers more than 9,000 interactions with diseases, medications and allergies for its personalized recommendations. Therefore, it doesn´t make any difference whether our customer is a 23-year-old triathlete, a 30-year-old pregnant woman or a 65-year-old diabetes patient. Our personalization algorithm generates the optimal nutrient supply for each person based on their individual needs.

Philipp Merk, one of the founders and responsible for product development at LOEWI

The results of our first pilot study are very convincing. On average, more than 75% of customers and patients significantly improved their nutrient balance within the first three months of using the LOEWI concept. We are now focusing on making personalized nutrition and health available to everyone.

Philipp Merk, one of the founders and responsible for product development at LOEWI

LOEWI GmbH is a scientific spin-off of the TU Munich with the mission to make personalized health and nutrition available to everyone through the combination of science and technology. LOEWI’s patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI’s health profile (medical software class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of customers and patients.

Agnes-Pockels-Bogen 1
80992 München
Phone: +49 89 23792242

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, techdriven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital business models, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.

Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies. Our fund investors.


High-Tech Gründerfonds Management GmbH
Dr. Marie Asano
Schlegelstraße 2
53113 Bonn
T.: +49 228 823 00 163

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Team GlassDollar
31. May 2023

GlassDollar connects leading corporations to cutting-edge startups to build the world of tomorrow

GlassDollar raises €2M (led by HTGF) to match startup solutions to corporate challenges and design the world of tomorrow. Through data, software and operational support, GlassDollar provides a Venture Clienting OS that helps corporate innovators use startup solutions to achieve tangible impact — on their organization and the world. Customers include leading innovation units at Bosch Siemens home-appliances, Volkswagen, A2A, LG, MTU and Infineon. In March, GlassDollar closed a
30. May 2023

A European champion for fusion: Proxima Fusion spins out of the Max Planck Institute for Plasma Physics

Munich, May 30th 2023 - Proxima Fusion, a fusion start-up that is designing fusion power plants based on the stellarator concept, completed its pre-seed fundraising of €7m. The fundraising is co-led by Plural and UVC Partners, and joined by High-Tech Gründerfonds (HTGF) and the Wilbe Group. Proxima Fusion is the first spin-out from the Max Planck Institute for Plasma Physics (IPP). The startup was founded by former scientists and engineers from the Max Planck IPP, MIT, and Google-X. Th
23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million. The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific tea